Dihexa side effects and risks

Reported side effects

• Changes in behavior or face recognition: One report described more rigid routines and worse face recognition; no incidence estimate., moderate. Stop and discuss new changes with a clinician. Other medicines confound the report. (source)
• Sleepiness or exhaustion: A commenter reported exhaustion about 2 hours after oral 8 mg and again after 4 mg., moderate. Avoid driving when sleepy; seek review of new or persistent symptoms. (source)
• Overfocus and emotional dulling: Reported with oral 50 mg plus stimulants; no causal attribution or rate is possible., moderate (source)
• Allergy or infection related to the product: General unapproved product risk, not a measured dihexa event rate., serious. Breathing problems or spreading injection-site infection need urgent care. (source)

Stop and get help if

• Trouble breathing, throat or tongue swelling, collapse or fainting after exposure.: Call emergency services now. These can be signs of anaphylaxis.
• A hot, painful, spreading red injection site, especially with fever or feeling very ill.: Seek urgent medical care. Confusion, fainting or fast breathing needs emergency care.

Who should avoid it

• pregnant: Precautionary block: no pregnancy safety data for directly taking dihexa.
• breastfeeding: Precautionary block: milk transfer and infant effects are unknown.
• tryingToConceive: Precautionary block: fertility and early-pregnancy safety are unknown.
• under18: Precautionary block: no pediatric dosing or developmental safety data.
• activeCancer: Proposed HGF/MET growth signaling raises a theoretical cancer-growth concern. No safe exposure is established.
• cancerHistory: Discuss prior cancer or unexplained new lumps with the treating clinician; the possible growth-signaling risk is unquantified.
• psychiatricCondition: Anecdotes include behavior changes. Existing psychiatric illness and psychoactive-drug combinations need review.
• kidneyDisease: No direct-dihexa human clearance data or kidney-dose adjustment is established.
• liverDisease: No direct dihexa human metabolism data or liver-dose adjustment is established.
• testedAthlete: Unapproved pharmacological substances are prohibited under the 2026 List; growth-factor rules may also apply.

Interactions

• Other nootropics and psychoactive drugs: No interaction studies establish safe combinations. Stimulant and nootropic stacks confound reports of mood, sleep and focus changes.

Product quality risks

• General peptide warnings describe wrong ingredients, wrong amounts and microbial or solvent contamination. No independent market survey of this compound was located.
• A purity percentage cannot establish dose, identity, sterility or clinical safety.
• Research-use labeling does not mean a product meets medicine quality standards.